Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

March 2, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2031

Conditions
Breast Cancer
Interventions
DRUG

Palbociclib 125mg

Palbociclib at a dose of 125 mg should be taken by mouth with food on 21 days on 7 days off schedule (meaning: on Days 1-21of each 28-day cycle). If a subject misses a day's dose entirely, she must be instructed not to make it up the next day but just take her regular dose at the next assigned time. If a subject vomits any time after taking a dose, she must be instructed not to retake the dose but resume subsequent dosing at the next assigned time. If a subject inadvertently takes an extra dose during a day, she must be instructed to not take the next day's dose.

Trial Locations (1)

68198

RECRUITING

Unversity of Nebraska Medical Center, Omaha

All Listed Sponsors
lead

University of Nebraska

OTHER